Colum J Smith

发表

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

V. Rusch, R. Livingston, D. Gandara, 2009, The Lancet.

Oncologists and family physicians. Using a standardized letter to improve communication.

Colum J Smith, T. Braun, N. Hagen, 2003, Canadian family physician Medecin de famille canadien.

Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.

W. Curran, H. Choy, W. Roa, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

Wilson Roa, T. Whelan, Y. Ung, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-154 Impact of maintaining Hb with epoetin alfa on time toprogression (TTP), overall survival (OS), quality of life (QOL) and transfusion reduction in limited disease SCLC patients

A. Bezjak, G. Perry, Colum J Smith, 2005 .

Research and innovative treatment

Colum J Smith, Jane Lynch, L. Terry, 2010 .

B. Movsas, Colum J Smith, C. Langer, 2005 .

Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309)

Michael R. Green, D. Gandara, F. Shepherd, 2005 .

Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy

Colum J Smith, A. Brade, G. Bebb, 2011, Cancer Chemotherapy and Pharmacology.

Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.

R. Komaki, B. Movsas, Colum J Smith, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer.

P. Ellis, Colum J Smith, C. Butts, 2010, Clinical lung cancer.

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.

P. Ellis, P. Ellis, A. Price, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15).

A. Bezjak, M. Brundage, D. Tu, 2002, International journal of radiation oncology, biology, physics.

Randomized trial of amifostine in locally advanced non-small cell lung cancer (NSCLC) patients receiving chemotherapy and hyperfractionated radiation (HRT): Long-term survival results of Radiation Therapy Oncology Group (RTOG) 9801

Benjamin Movsas, Nicos Nicolaou, R. Komaki, 2007 .

PL-4 Phase III study of concurrent chemotherapy and full course radiotherapy (CT/RT) versus CT/RT induction followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): First outcome analysis of North American Intergroup trial 0139 (RTOG 93-09)

D. Gandara, K. Albain, A. Turrisi, 2003 .

The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.

J. Bradley, R. Komaki, Y. Lawrence, 2013, Lung cancer.

Concurrent weekly carboplatin and radiotherapy for nasopharyngeal carcinoma: report of a joint phase II study.

J. Mackey, T. Reiman, Colum J Smith, 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A multi-centre, open-label study to assess the safety of Stimuvax (BLP25 liposome vaccine or L-BLP25) in non-small cell lung cancer (NSCLC) patients (pts) with unresectable stage III disease

P. Ellis, Colum J Smith, C. Butts, 2007 .